January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
Betamethasone is more effective long-term for alopecia areata than hydroxychloroquine.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
2 citations
,
January 2013 in “Iraqi journal of Medical Sciences” 12 citations
,
January 2018 in “PubMed” Y-27632 helps hair follicle stem cells grow and keep their abilities.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
September 2022 in “Health and Medical Journal” Minoxidil and oral antioxidants helped improve hair growth in a patient with hair loss due to lupus.
16 citations
,
March 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
January 2020 in “Indian Journal of Forensic Medicine & Toxicology” Oral cyclosporine is an effective and safe treatment for severe alopecia areata.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
9 citations
,
May 2019 in “Journal of dermatological treatment” Apremilast helps regrow hair in hard-to-treat alopecia areata.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
June 2024 in “Advances in therapy” IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
54 citations
,
July 1994 in “Journal of Dermatological Science” FK506 may stimulate hair growth when applied to the skin.
March 2025 in “JAAD International” Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.
May 2025 in “Pakistan Armed Forces Medical Journal” Dithranol is more effective than Tacrolimus for hair regrowth in alopecia areata.
February 2024 in “Current Drug Delivery” The new minoxidil emulgel with marine-based polymers shows effective controlled drug release for hair growth treatment.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
Minoxidil is strongly linked to heart problems, and machine learning can improve drug safety checks.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.